Skystar Bio-Pharmaceutical Company

Skystar Bio-Pharmaceutical — Investor Presentation (October 2009)

30 slides from Skystar Bio-Pharmaceutical's investor presentation, Oct 14, 2009

  1. Slide 1: Skystar Bio-Pharmaceutical Co., Ltd.

    Slide 1: Skystar Bio-Pharmaceutical Co., Ltd.

    bard SKYSTAR pad Bio-PHARMACEUTICAL CO.,LTD. SKYSTAR Weibing Lu, Chairman and CEO R. Scott Cramer, Director

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements in this presentation may be "forward-looking statements” within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current management expectations that involve risks and uncertainties that may result

  3. Slide 3: Company Overview

    Slide 3: Company Overview

    Company Overview Leading China-based producer and distributor of veterinary medicines, vaccines, microorganisms and feed additives » GMP production facilities and processes » Headquartered in Xi’an, Shaanxi Province, China = 216 employees «= Only U.S. listed veterinary supply company in China

  4. Slide 4: 2009 Recent Events

    Slide 4: 2009 Recent Events

    2009 Recent Events

  5. Slide 5: Skystar Snapshot

    Slide 5: Skystar Snapshot

    Skystar Snapshot a Stock Price (Oct. 8, 2009) $15.90 52 Week Range $ 1.25 - $22.49 Shares Outstanding 3.5M Market Cap $55.33 P/E (TTM — Adjusted)* 4.96 1HO9 Revenues $10.1M 1HO9 Net Income / Adjusted Net Income* $0.50 / $1.28 ~ Adjusted net income excludes a net $1.44 million loss in 1H09 for the ch

  6. Slide 6: Why Invest in Skystar

    Slide 6: Why Invest in Skystar

    Why Invest in Skystar v Leader in young, fragmented industry: demand exceeds supply Compelling market opportunity Extensive product lines covering all key segments of the animal ‘arming industry Large, established sales and distribution network Diverse customer base covers all 29 farm producing prov

  7. Slide 7: Growing Industry

    Slide 7: Growing Industry

    Growing Industry Consolidation of family owned/operated farms and improved technology are driving demand and growth in the veterinary industry > China is the world’s largest producer of poultry and livestock >» Government supports rapid development of modernization > GMP certification required by PR

  8. Slide 8: Products Lines Address Major Industry Segments

    Slide 8: Products Lines Address Major Industry Segments

    Products Lines Address Major Industry Segments Year ended 12/31/08 asa Percentage of Total Veterinary Medications $17,535,757 68%| $ 7,146,031 56% Micro-organism $ 5,868,623 23% | $ 4,087,025 32% Feed Additives $ 1,189,108 5%| $§ 663,455 5% Veterinary Vaccines $ 990,958 4%| $ 879,039 T% Total $25,58

  9. Slide 9: Veterinary Medications

    Slide 9: Veterinary Medications

    Veterinary Medications Year ended 12/31/08 Veterinary Medications $17,535,757 as a Percentage of Total 68% | $ 7,146,031 Total $25,584,446 100% | $12,775,550 140 products » 34 drugs approved in 2008 > Target: 40 drug approvals in 2009 » Focus on higher margin products SkysTar WES 0 Pranmsceumcal co,

  10. Slide 10: Micro-organism

    Slide 10: Micro-organism

    Micro-organism r Year ended 12/31/08 as a Percentage of Total Micro-organism $ 5,868,623 23% | $ 4,087,025 32% Total $25,584,446 100% | $12,775,550 100% 13 products » In house production of microbial strain significantly reduced production costs in 2008 » Constructing new production facility project

  11. Slide 11: Feed Additives

    Slide 11: Feed Additives

    Feed Additives Year ended 12/31/08 Feed Additives $ 1,189,108 $ 663,455 Total $25,584,446 $12,775,550 10 products » Increase yield > Improve health of livestock

  12. Slide 12: Veterinary Vaccines

    Slide 12: Veterinary Vaccines

    Veterinary Vaccines 1 Year ended 12/34/08 as a Percentage of Total Veterinary Vaccines $ 990,958 4% | $ 879,039 % Total $25,584,446 100% | $12,775,550 100% 10 products (active and inactive) » Constructing new production facility projected to increase production capacity by 2,300% >» Initiate product

  13. Slide 13: Effective R&D Capabilities

    Slide 13: Effective R&D Capabilities

    Effective R&D Capabilties Xi’an R&D Facilities Shanghai R&D Facilities Over 25 researchers responsible for developing new medicines and 5 researchers from the Chinese vaccines in response to epidemics, Academy of Agricultural Sciences pandemics and diseases Two Lab: Responsible for evaluating and zi

  14. Slide 14: Bringing Products to Market

    Slide 14: Bringing Products to Market

    Bringing Products to Market Launched several products targeting porcine reproductive and respiratory syndrome (PRRS), aka Blue Ear Disease » April, 2007: launched Chinese Goldthread (Huanglian) Detoxification Powder ("CGDP") » July, 2007: launched First Aid Kit for Swine High Fever Syndrome » Cures

  15. Slide 15: Customers and Distribution

    Slide 15: Customers and Distribution

    Customers and Distribution 5

  16. Slide 16: Skystar's Competitive Advantages

    Slide 16: Skystar's Competitive Advantages

    Skystar’s Competitive Advantages Only U.S. listed veterinary supply company in China Largest competitors are state-owned enterprises Established over 350 franchise stores in 2007-2008 Distribution network covering 29 provinces in China Majority of competitors only offer 1-2 product lines High barrie

  17. Slide 17: Growth Strategy

    Slide 17: Growth Strategy

    Growth Strategy + 40 new product introductions planned for 2009 In igere| uce New * Covers all four product lines + Leverage R&D capabilities to continue to add to portfolio P rod U cts and increase market share Expa n d * Two new facilities scheduled for completion in late 4Q09 Man ufactu ring + Bu

  18. Slide 18: Annual Revenue Growth

    Slide 18: Annual Revenue Growth

    Annual Revenue Growth $30.00 $25.00 $20.00 $15.00 $10.00 $5.00 $0.00 $25.58 Revenue (SMM) $9.80 $6.00 $4.00 mE = 2003 2004 2005 2007 $15.10 it 2008 18

  19. Slide 19: 1H Revenue

    Slide 19: 1H Revenue

    1H Revenue $14.00 $12.00 $10.07 $10.00 $8.00 $7.16 $8.00 $4.74 $4.00 $2.00 $0.00 HOT 1HO8 1HO9 laid Bio. PHARMACEUTICAL CO.LTD. 19

  20. Slide 20: Annual Gross Margin Expansion

    Slide 20: Annual Gross Margin Expansion

    Annual Gross Margin Expansion $14.00 $12.00 $10.00 $8.00 $6.00 $4.00 $2.00 $0.00 latad Bio. PHARMACEUTICAL CO.,LTD, o $12.78 7 60.0% 4% 7% 250.0% are 4.7% $8.34 40.0% 30.0% $4.40 00% $3.00 $1.80 10.0% $0.60 [ ] = : , , f aa% 2003 2004 2005 2006 2007 2008 lam Gross Margin (SMM) —- Gross Margin (%) 20

  21. Slide 21: 1H Gross Margin Expansion

    Slide 21: 1H Gross Margin Expansion

    1H Gross Margin Expansion $6.00 + $3.00 $2.63 $3.70 51.3% $5.16 (HOT | Gross Margin (SMM) 4HOB -* Gross Margin (%) 1HO9 a 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 21

  22. Slide 22: High Margin Products

    Slide 22: High Margin Products

    High Margin Products 12 Months Ended 12/31/08 Revenues Gross Margin Veterinary Medications $17,535,757 | $7,146,031 Micro-organism 5,868,623 4,087,025 Feed Additives 1,189,108 663,455 Vaccines 990,958 879,039 Total $25,584,446 $12,775,550

  23. Slide 23: Annual Adjusted Net Income Growth

    Slide 23: Annual Adjusted Net Income Growth

    Annual Adjusted Net Income Growth 7.00 + $6.70 — 30.0% 6.2% 6.00. | 25.0% 5.00 + + 20.0% 4.00 + | 15.0% 3.00 + + 10.0% 2.00 + 1.00 + | 5.0% 0.00 0.0% 2003 2004 2005 2006 2007 2008 EE Net Income ($MM) ~~ —@— Profit Margin

  24. Slide 24: 1H Adjusted Net Income

    Slide 24: 1H Adjusted Net Income

    1H Adjusted Net Income $4.00 $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $0.00 23.7% $2.39 1HO7 1HO8 1HO9 (mNet Income ($MM) —¢-Profit Margin 24.5% 23.5% 22.5% 21.5% 20.5% 19.5% 18.5% 24

  25. Slide 25: Select Balance Sheet Data

    Slide 25: Select Balance Sheet Data

    Select Balance Sheet Data As of June 30, 2009 Cash and Restricted Cash $411,000 Current Assets $17.6M Current Liabilities $6.36M On July 7, 2009, Skystar completed an equity offering for gross proceeds of ~21.0M Skustar WEN Bo Prarnmaceumcal co.L7o.

  26. Slide 26: Weibing Lu - Chairman and CEO

    Slide 26: Weibing Lu - Chairman and CEO

    Weibing Lu - Chairman and CEO =» Founded Xian Tianxing Bio- Pharmaceutical Co., Ltd. (our operating company in China) in 1997 « BS from Wuhan University in 1985 and MBA from Xi'an Jiaotong University in 1999 « Awarded Outstanding Entrepreneur of Xi'an Feed Industry in 2002 « Appointed as a Director

  27. Slide 27: Wei Wen - Director and Vice General Manager

    Slide 27: Wei Wen - Director and Vice General Manager

    Wei Wen - Director and Vice General Manager « Secretary of the Board and Vice GM since founding of the Company « Graduated from Xi’an University of Science and Industry in 1986 « Manager and Vice GM at the Sales Department of two companies before joining Skystar FA Sxustar $e Bo PHaRmAceurAL co.L-To

  28. Slide 28: Bennet P. Tchaikovsky, CPA, Esq. - CFO

    Slide 28: Bennet P. Tchaikovsky, CPA, Esq. - CFO

    Bennet P. Tchaikovsky, CPA, Esq. - CFO « Part-time CFO of China Jo-Jo Drugstores, Inc. (OTCBB: CJJD.OB) « Former CFO of Innovative Card Technologies, Inc. (OTCBB: INVC) E Director of Ever-Glory International Group (NYSE AMEX: EVk) « Director of Sino Clean Energy Inc. (OTCBB: SCLX.OB) « Graduate of S

  29. Slide 29: Erna Gao - VP Finance & Administration

    Slide 29: Erna Gao - VP Finance & Administration

    Erna Gao - VP Finance & Administration « Served as our Chief Financial Officer from March 2004 through May 2008 « Former Chief Accountant at Dongda Petroleum Company « Graduated from Xi'an TB University with a degree in Accounting 29

  30. Slide 30: Scott Cramer, Director & US Spokesperson

    Slide 30: Scott Cramer, Director & US Spokesperson

    Scott Cramer, Director & US Spokesperson » Former CEO, CFO of The Cyber Group » Founder and President of Cramer & Associates, a firm specializing in rh} retirement management, estate planning and investments » Registered Representative - Series 7, 63, 65 30

Source: SEC EDGAR · 8-K filed Oct 14, 2009

More decks from Skystar Bio-Pharmaceutical Company